首页 | 本学科首页   官方微博 | 高级检索  
检索        

大剂量阿糖胞苷治疗急性髓性白血病缓解后患者15例分析
引用本文:祝辉,高峰.大剂量阿糖胞苷治疗急性髓性白血病缓解后患者15例分析[J].中国全科医学,2006,9(24):2070-2071.
作者姓名:祝辉  高峰
作者单位:1. 110031,辽宁省沈阳市第四人民医院血液科
2. 中国医科大学附属第一医院
摘    要:目的观察急性髓性白血病(AML)缓解后应用大剂量阿糖胞苷(HD-Ara-C)联合常规化疗治疗的疗效。方法将29例AML患者随机分为治疗组和对照组。治疗组15例患者在常规化疗基础上第1、3、5d用HD-Ara-C持续3h以上静脉滴注,1~2次/年。对照组患者行常规化疗。比较两组患者治疗后1年、3年和5年的无病生存(DFS)情况。结果两组患者治疗后1年、3年和5年的DFS情况间差别均有显著性意义(P<0·01)。结论HD-Ara-C用于AML缓解后的维持强化治疗疗效较好,可延长患者的DFS期。

关 键 词:大剂量阿糖胞苷  白血病  髓样  急性  无病生存
文章编号:1007-9572(2006)24-2070-02
收稿时间:2006-10-24
修稿时间:2006年10月24

Effects of High-dose Cytarabine Treating 15 Cases Involving Remission of Acute Myeloid Leukemia
ZHU Hui,GAO Feng.Effects of High-dose Cytarabine Treating 15 Cases Involving Remission of Acute Myeloid Leukemia[J].Chinese General Practice,2006,9(24):2070-2071.
Authors:ZHU Hui  GAO Feng
Abstract:Objective To observe the therapeutic effects of high-dose cytarabine (HD-Ara-C) in the treatment of patients with remission of acute myeloid leukemia (AML).Methods 29 cases with AML were randomly divided into treatment group (15 cases) and control group (14 cases).Patients in treatment group were carried HD-Ara-C intravenously on the first,third and fifth day,at least three hours,once or twice per year on the basis of routine chemical therapy while patients in control group were only carried routine chemical therapy.The disease-free survival (DFS) after the first,third and fifth year between two groups were compared.Results The difference of DFS after the first,third and fifth year between two groups was significant (P<0.01).Conclusion HD-Ara-C has better therapeutic effect for patients with forced treatment after the remission of AML,which can prolong the time of DFS.
Keywords:High-dose cytarabine  Leukemia  myeloid  acute  Disease-free survival
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号